Miltefosine and Paromomycin
Phase 3Small molecule
Miltefosine and Paromomycin is one of 37 small molecule programs targeting Cutaneous Leishmaniasis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
56 competitors in Cutaneous Leishmaniasis
#DrugCompanyPhaseTrials
1Garamycin
SSchering-Plough
Approved
Abelcet
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Levaquin
WWim Janssens
Approved
Impavido
KKnight Therapeutics (USA) Inc
Phase 3
Meglumine Antimoniate
UUniversity of Brasilia
Approved
Pentam
FFresenius Kabi Oncology Ltd.
Phase 3
Aldara
BBausch Health Americas, Inc.
Phase 3
Diflucan
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Cipro
BayerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Miltefosine and Paromomycin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDrugs for Neglected Diseases